What rosuvastatin dose is equivalent to a Nexletol (bempedoic acid) 180 mg tablet?

Nexletol (Bempedoic Acid) 180 mg is NOT Equivalent to Any Specific Rosuvastatin Dose

Nexletol 180 mg and rosuvastatin are fundamentally different medications that work through distinct mechanisms and cannot be directly dose-converted or substituted for one another. Bempedoic acid is an ATP-citrate lyase inhibitor designed to be used in addition to statins like rosuvastatin, not as a replacement 1, 2.

Why Direct Equivalence Doesn't Exist

Different Mechanisms of Action

• Rosuvastatin: Inhibits HMG-CoA reductase directly in all tissues
• Bempedoic acid: Inhibits ATP-citrate lyase (upstream of HMG-CoA reductase) and is a prodrug activated only in the liver, not in muscle tissue 3

LDL-C Lowering Capacity Differs Substantially

Rosuvastatin monotherapy:

• High-intensity doses (≥20 mg) reduce LDL-C by 45-50% 4
• Dose range: 5-40 mg daily 5

Bempedoic acid 180 mg:

• When added to statin therapy: 17-18% additional LDL-C reduction 1
• As monotherapy in statin-intolerant patients: 20-39% LDL-C reduction 6

The Synergistic Relationship

The key insight is that bempedoic acid 180 mg combined with a low-dose statin achieves similar LDL-C lowering as quadrupling that statin dose 7. For example:

• Rosuvastatin 20 mg + bempedoic acid 180 mg ≈ rosuvastatin 80 mg alone (both ~54% LDL-C reduction)
• Rosuvastatin 5 mg + bempedoic acid 180 mg would approximate rosuvastatin 20 mg alone

This synergy occurs because both drugs inhibit different steps in the same cholesterol synthesis pathway, creating complementary rather than equivalent effects 7, 3.

Clinical Context for Use

Bempedoic acid is FDA-approved for:

1. Reducing cardiovascular events in patients unable to take recommended statin therapy 2
2. As adjunct therapy when statins alone don't achieve LDL-C goals 1, 2

Current guideline positioning 4:

• First-line: High-intensity statin (rosuvastatin ≥20 mg or atorvastatin ≥40 mg)
• Second-line: Add ezetimibe if goals not met
• Third-line: Add bempedoic acid for statin-intolerant patients OR consider PCSK9 inhibitors

Critical Caveats

• Never substitute bempedoic acid for a statin in patients who can tolerate statins—statins remain first-line therapy with proven mortality benefit 4
• Bempedoic acid does not replace rosuvastatin; it complements it
• The 180 mg dose is the only approved dose of bempedoic acid 2
• Monitor for hyperuricemia (26% incidence) and tendon rupture risk (0.5-1.2% incidence) with bempedoic acid 2

If the question is about switching a patient from rosuvastatin to bempedoic acid: This should only occur in documented statin intolerance, and you cannot predict an equivalent dose—expect approximately 20-30% LDL-C reduction with bempedoic acid monotherapy versus 45-50% with high-intensity rosuvastatin 6, 8.